This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
What Are the National and Global Recommendations for Pneumococcal Vaccination in HIV-infected Adults?
Various global and national guidelines have specific recommendations for pneumococcal vaccines in HIV-infected individuals. The ACIP 2019 guidelines recommend the use of PCV13 and PPSV23 in all HIV-infected adults aged ≥50 years; 1 dose of PCV13 and 2 doses of PPSV23 (1st dose ≥8 weeks after PCV13, and 2nd dose ≥5 years after first PPSV23 dose) in adults aged 50 to 64 years. In adults aged ≥65 years, 1 dose of PCV13 is recommended if not previously vaccinated, and 1 dose of PPSV13 should be given ≥8 weeks after PCV13 and ≥5 years after any PPSV23 received at an age <65 years.1
The IAOH recommends the use of PCV13 and PPSV23 in series in all HIV-infected adults aged ≥50 years; 1 dose of PCV13 should be administered first followed by 1 dose of PPSV23 at least 1 year after receiving PCV13.2 The IMA (2018) recommends the use of PCV13 in adults aged ≥50 years when diagnosed with HIV. A maximum 3 doses of PPSV23 can be administered to these adults, with a minimum gap of 5 years; the first PPSV23 dose should be administered with a minimum gap of ≥8 weeks from PCV13 administration, second dose a minimum of 5 years after that and the third dose should be administered at the age of ≥65 years.3
ACIP, Advisory Committee on Immunization Practices; HIV, human immunodeficiency virus; IAOH, Indian Association of Occupational Health; IMA, Indian Medical Association; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.